US5563045A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Chimeric procoagulant proteins
Assignee: Genetics Institute LLC
•
Filing: 1993-09-14
•
Granted: 1996-10-08
•
Expires: 2013-09-14
Abstract
Abstract Provided are porcine factor VIII nucleotide sequences and hybrid sequences encoding human/porcine chimeric factor VIII-type procoagulant proteins. DNAs encoding such chimeric factor VIII-type procoagulant proteins, pharmaceutical compositions containing such chimeric factor VIII-type procoagulant proteins, and methods of treating hemophilia using such chimeric factor VIII-type procoagulant proteins are also provided.
Inventors
- 👤 Debra Pittman
- 👤 Alnawaz Rehemtulla
- 👤 John M. Wozney
- 👤 Randal J. Kaufman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 22:05
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
70 words
A composition comprising a nucleic acid encoding factor VIII having factor VIII coagulant activity selected from the group consisiting of: (a) human domains A1, B, A3, C1; and porcine domain A2; (b) human domains B, A3, C1 and C2; and porcine domains A1 and A2; (c) human domains A1, A3, C1 and C2; and porcine A2; and (d) human domains A3, C1 and C2; and porcine domains A1 and A2.
Claim 2
Dependent Claim
70 words
A composition comprising a nucleic acid encoding factor VIII having factor VIII coagulant activity selected from the group consisiting of: (a) human domains A1, B, A3, C1; and porcine domain A2; (b) human domains B, A3, C1 and C2; and porcine domains A1 and A2; (c) human domains A1, A3, C1 and C2; and porcine A2; and (d) human domains A3, C1 and C2; and porcine domains A1 and A2.
Claim 3
Dependent Claim
16 words
A procaryotic or eucaryotic host cell transformed or transfected with a nucleic acid of claim 1.
Claim 4
Dependent Claim
23 words
The prokaryotic transformed host cell of claim 2 which is E. coli DH5 cells designated as por302 and corresponding to ATCC No: 69387.
Claim 5
Dependent Claim
14 words
A viral or circular nucleic acid plasmid comprising a nucleic acid of claim 1.
Claim 6
Dependent Claim
22 words
The viral or circular nucleic acid plasmid of claim 4 further comprising an expression control sequence operatively associated with said nucleic acid.
Claim 7
Dependent Claim
42 words
A method for the production of factor VIII comprising: growing, in culture, a host cell transformed or transfected with a nucleic acid of claim 1, isolating from said host cell and culture, the polypeptide product of the expression of said nucleic acid.
Claim 8
Dependent Claim
37 words
A method for the production of factor VIII comprising: disposing a nucleic acid of claim 1 in a cell free transcription and translation system; and isolating from said system the polypetide expression product of said nucleic acid.
Claim 9
Dependent Claim
13 words
The method of claim 6, wherein said factor VIII is human/porcine factor VIII.
Claim 10
Dependent Claim
24 words
A procaryotic or eucaryotic host cell transformed or transfected with nucleic acid selected from the group consisting of the nucleic acid of claim 1.
Claim 11
Dependent Claim
24 words
A viral or circular nucleic acid plasmid comprising a nucleic acid sequence selected from the group consisting of the nucleic acid of claim 1.
Claim 12
Dependent Claim
22 words
The viral or circular nucleic acid plasmid of claim 10 further comprising an expression control sequence operatively associated with said nucleic acid.
Claim 13
Dependent Claim
44 words
A method for the production of factor VIII activity comprising: growing, in culture, a host cell transformed or transfected with a nucleic acid of claim 1 and isolating from said host cell, or culture, the polypeptide product of the expression of said nucleic acid.
Claim 14
Dependent Claim
38 words
A method for the production of factor VIII activity comprising: disposing a nucleic acid of claim 1 in a cell free transcription and translation system; and isolating from said system the polypeptide expression product of said nucleic acid.
Claim 15
Dependent Claim
17 words
The method of claim 12 or 13, wherein said factor VIII activity is human/porcine factor VIII activity.
Claim 16
Dependent Claim
38 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and factor VIII amino acids corresponding to: human 1-335 and 373-2332 of SEQ ID NO. 2 and porcine 138-174 of SEQ ID NO. 4.
Claim 17
Dependent Claim
38 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and factor VIII amino acids corresponding to: human 1-335 and 373-2332 of SEQ ID NO. 2 and porcine 138-174 of SEQ ID NO. 4.
Claim 18
Dependent Claim
28 words
The nucleic acid of claim 15 encoding amino acids corresponding to: human 1-335 and 741-2332 of SEQ ID NO. 2 and porcine 138-541 of SEQ ID NO. 4.
Claim 19
Dependent Claim
38 words
A composition comprising a nucleic acid encoding a protein having factor VII coagulant activity and Factor VII amino acids corresponding to: human 1-371 and 741-2332 of SEQ ID NO. 2 and porcine 174-541 of SEQ ID NO. 4.
Claim 20
Dependent Claim
38 words
A composition comprising a nucleic acid encoding a protein having factor VII coagulant activity and Factor VII amino acids corresponding to: human 1-371 and 741-2332 of SEQ ID NO. 2 and porcine 174-541 of SEQ ID NO. 4.
Claim 21
Dependent Claim
37 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and Factor VII amino acids corresponding to: human 1-699 and 741-2332 of SEQ ID NO. 2 and porcine 501-541of SEQ ID NO. 4.
Claim 22
Dependent Claim
37 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and Factor VII amino acids corresponding to: human 1-699 and 741-2332 of SEQ ID NO. 2 and porcine 501-541of SEQ ID NO. 4.
Claim 23
Dependent Claim
41 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and Factor VII amino acids corresponding to: human 1-335,373-699, and 74114 2332 of SEQ ID NO. 2 and porcine 138-174 and 501-541 of SEQ ID NO. 4.
Claim 24
Dependent Claim
41 words
A composition comprising a nucleic acid encoding a protein having factor VIII coagulant activity and Factor VII amino acids corresponding to: human 1-335,373-699, and 74114 2332 of SEQ ID NO. 2 and porcine 138-174 and 501-541 of SEQ ID NO. 4.
Claim 25
Independent Claim
44 words
A method for the production of porcine factor VIII activity comprising: growing, in culture, a host cell transformed with a nucleic acid of SEQ ID No:3; and isolating from said host cell, or culture, the polypeptide product of the expression of said nucleic acid.
Claim 26
Independent Claim
44 words
A method for the production of porcine factor VIII activity comprising: growing, in culture, a host cell transformed with a nucleic acid of SEQ ID No:3; and isolating from said host cell, or culture, the polypeptide product of the expression of said nucleic acid.
Claim 27
Independent Claim
46 words
A method for the production of porcine factor VIII activity comprising: disposing all or part of a nucleic acid of SEQ ID NO:3 in a cell free transcription and translation system; and isolating from said system the polypeptide product of the expression of said nucleic acid.
Claim 28
Independent Claim
46 words
A method for the production of porcine factor VIII activity comprising: disposing all or part of a nucleic acid of SEQ ID NO:3 in a cell free transcription and translation system; and isolating from said system the polypeptide product of the expression of said nucleic acid.
Claim 29
Dependent Claim
20 words
A factor VIII expression product of the in vitro or in vivo expression of a nucleic acid of claim 1.
Claim 30
Dependent Claim
8 words
An amino acid sequence of SEQ ID NO:4.
Claim 31
Dependent Claim
8 words
An amino acid sequence of SEQ ID NO:4.
Claim 32
Dependent Claim
81 words
A composition comprising a nucleic acid encoding factor VIII having factor VIII coagulant activity comprising two domains substantially duplicative of a sequence of amino acids comprising a domain selected from (a) and a domain selected from (b), wherein: (a) is one or more members selected from the group consisting of human domains A1, A2, B, A3, C1 and C2, and (b) is one or more members selected from the group consisting of porcine domains A1, A2, B, A3, C1, and C2.
Claim 33
Dependent Claim
81 words
A composition comprising a nucleic acid encoding factor VIII having factor VIII coagulant activity comprising two domains substantially duplicative of a sequence of amino acids comprising a domain selected from (a) and a domain selected from (b), wherein: (a) is one or more members selected from the group consisting of human domains A1, A2, B, A3, C1 and C2, and (b) is one or more members selected from the group consisting of porcine domains A1, A2, B, A3, C1, and C2.
Claim 34
Dependent Claim
18 words
A method for treating hemophilia comprising the step of administering the factor VIII expression product of claim 22.
Claim 35
Dependent Claim
12 words
A pharmaceutical composition comprising the factor VIII expression product of claim 22.
References Cited (Backward Citations)
WO1993020093A1
Cited
US5364771A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-10-08 | 2000-04-08 | 2000-10-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-10-08 | 2004-04-08 | 2004-10-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-10-08 | 2008-04-08 | 2008-10-08 | $7700.00 | Window Closed / Lapsed |